Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company's lead candidate, seralutinib (also known as GB002), is an investigational inhaled small molecule inhibitor of platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT, designed for delivery via a dry powder inhaler. Gossamer Bio is advancing seralutinib through Phase 3 clinical trials, including the PROSERA study for PAH and the SERANATA study for PH-ILD. Additionally, the company is advancing RT234 under an option agreement with Respira Therapeutics as a complementary therapeutic opportunity in PAH and PH-ILD. The company engages with the U.S. Food and Drug Administration to define regulatory paths forward and is preparing for potential New Drug Application submissions.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage gossamerbio.com
Sector Healthcare IR page ir.gossamerbio.com
Tags
pulmonary hypertension, pulmonary arterial hypertension, interstitial lung disease, inhaled therapeutics, small molecule inhibitors, rare diseases, clinical-stage, pdgfr inhibitors, csf1r inhibitors, c-kit inhibitors, seralutinib, GB002, RT234, PROSERA, SERANATA, TORREY, Respira Therapeutics
Press page —

Metrics

Valuation  
Market cap $ 72.479M
Market cap (USD) $ 72.479M
P/E -1.51
PEG —
P/BV -0.59
P/S 0.92
P/OCF -0.46
P/FCF -0.46
Dividend yield —
Turnover / mcap —
Returns  
ROE 138.8%
ROI -224.9%
ROIC -169.0%
Profit margin -351.5%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 52
Quality score -56.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 48.471M 114.701M — — — — — —
Net profit -170.37M -56.528M -179.817M -229.378M -234.004M -243.36M -180.307M -146.969M
Free cash flow -171.345M -3.468M -159.158M -187.442M -190.436M -177.863M -147.8M -54.534M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 3.1 0.9 0.91 2.17 11.31 9.67 15.63 —
Price performance 12m 2.43 -0.01 -0.58 -0.81 0.17 -0.38 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — — — — 0.00 5.34M 12.2M
↳ YoY growth +129.1%
Borrowings, current (USD) — — — — — 0.00 11.6M 11.6M 0.00 —
Borrowings, non-current (USD) — — — 28.5M 28.7M 29.1M 12M 814,000 0.00 —
Lease liabilities (USD) — — — 11.1M 11.3M 6.12M 6.43M 3.45M 5.36M 4.4M
Cash and deposits (USD) 60,000 315,000 105M 135M 486M 183M 112M 32.1M 46.1M 37.7M
Right-of-use assets (USD) — — — 10.3M 10.6M 5.48M 5.91M 3.13M 5.11M 4.13M
Net debt (borrowings + leases - cash) (USD) — — — -95.5M -446M -148M -81.9M -16.2M -40.7M —
Cash flow detail
Operating cash flow (USD) 20,000 -5.75M -51M -145M -176M -189M -187M -159M -3.47M -171M
Purchases of property, plant and equipment (USD) 0.00 0.00 3.49M -2.97M -1.5M -1.55M -410,000 0.00 0.00 -79,000
Change in receivables (cash effect) (USD) — — — — — — 0.00 0.00 -5.34M -6.89M
Change in payables (cash effect) (USD) 103,000 57,000 2.09M -1.4M 6.98M -4.43M -1.81M 3.99M -1.66M -2.75M
Interest paid (cash effect) (USD) — — -119,000 -1.48M -7.87M -12.7M -12.7M -12.3M -10.6M -10M
Share-based compensation (USD) 0.00 32,000 30.9M 20.8M 38.7M 32M 42.6M 28.5M 20.6M 10.6M
Operating cash flow before change in receivables (USD) — — — — — — -187M -159M 1.87M -164M
Free cash flow (OCF - PPE - intangibles) (USD) 20,000 -5.75M -54.5M -148M -178M -190M -187M -159M -3.47M -171M
Income detail
Research and development expense (USD) 0.00 891,000 55.3M 143M 161M 170M 171M 135M 138M 174M
↳ 5y CAGR +186.1% +19.6% -0.7% +1.6%
Total comprehensive income (USD) — -6.77M -147M -180M -243M -235M -230M -180M -55M -177M
Comprehensive income to owners (USD) — -6.77M -147M -180M -243M -235M -230M -180M -55M -177M
Reported Mar 24, 2020 Mar 24, 2020 Mar 24, 2020 Mar 24, 2020 Feb 26, 2021 Aug 9, 2022 Mar 13, 2025 Mar 13, 2025 Mar 13, 2025 Mar 17, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

– Structured Private Placement Provides $25 Million Upfront and Up to $125 Million of Additional Committed Capital Upon FDA Acceptance of the Seralutinib NDA –

– 1-for-80 Reverse Stock Split Completed in September 2026 –

- Cash, Cash Equivalents and Marketable Securities Totaled $51.2 Million as of September 30, 2026 -

SAN DIEGO—(BUSINESS WIRE)— November 10, 2026 — Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the third quarter ended September 30, 2026, and provided a business update.

“Submitting our first NDA marks an important milestone for Gossamer in our continued efforts to bring seralutinib to patients living with PAH,” said Faheem Hasnain, Chairman, Co-Founder and Chief Executive Officer of Gossamer Bio.

The following is a brief description of the matter voted upon at the special meeting of stockholders of Gossamer Bio, Inc. (the “Company”) held on October 27, 2026 (the “Special Meeting”) and the number of votes cast for or against, the number of abstentions and the number of broker non-votes with respect to the matter, as applicable. Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Company’s definitive proxy statement relating to the Special Meeting, dated as of and filed with the U.S. Securities and Exchange Commission on September 16, 2026 (the “Proxy Statement”).

Gossamer Bio, Inc. — Other Events Bull 0 Bear 0 Routine

On September 25, 2026, Gossamer Bio, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1), and the minimum bid price matter is now closed. The letter was pursuant to a previous letter received on April 8, 2026 from the Listing Qualifications Department of Nasdaq, indicating, as previously reported, that the Company was not then in compliance with the minimum bid price requirement because its common stock had failed to maintain a minimum bid price of $1.00 or more for 30 consecutive business days. As previously disclosed, on September 10, 2026, the Company effected a 1-for-80 reverse stock split of its common stock, and the Company’s common stock began trading on a split-adjusted basis on the Nasdaq Global Select Market on September 11, 2026.

Prompts

Gossamer Bio, Inc. (ticker GOSS), listed in United States.

ETFs Holding Gossamer Bio, Inc.

ETF Weight in ETF Shares Market value As of
ESSC 0.10% 204,551 $ 34.671K Jul 31, 2026